anti-inflammatory foods

One therapy, many targets: redefining ulcerative colitis treatment through fecal microbiota transplantation

5 April 2026

Rynikova M, Bojcukova V, Demeckova V.

Summary

What the study found

This review highlights that fecal microbiota transplantation (FMT) serves as a powerful multi-target therapy for ulcerative colitis by addressing the root causes of the disease simultaneously. Unlike conventional drugs that only suppress the immune system, FMT restores bacterial balance, repairs the gut lining, and retrains the immune response to promote lasting recovery.

Key findings

FMT promotes mucosal healing by strengthening the physical barrier of the gut, which prevents harmful substances from leaking into the body.
The procedure corrects gut dysbiosis by replacing inflammatory microbes with a diverse community of beneficial bacteria.
It functions as a potent immune modulator, reducing the overactive inflammatory signals that cause tissue damage in the colon.
The success of the treatment is highly dependent on donor selection and the specific preparation of the microbial material used for the transplant.

Practical takeaways

For those focused on health and longevity, this research emphasizes that the gut microbiome is a master regulator of systemic inflammation and immune age. Protecting your epithelial integrity through a high-fiber diet and fermented foods may help maintain the microbial diversity necessary to prevent chronic inflammatory "flares" and support long-term wellness.

Limitations

Current research lacks standardized protocols, leading to inconsistent results between different clinical trials and delivery methods. There are also ongoing concerns regarding the long-term safety and permanent survival of transplanted bacteria within a patient's existing ecosystem.

Abstract

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease driven by a multifactorial interplay between gut microbiota dysbiosis, immune dysregulation, and epithelial barrier dysfunction. Accurate diagnosis and a deeper understanding of UC pathogenesis are essential for developing durable and mechanism-based therapies. Despite major advances, conventional treatments such as immunosuppressants and biologics often fail to achieve sustained remission and carry significant adverse effects, underscoring the need for novel, multi-target interventions. This review synthesizes current insights into UC pathogenesis, diagnostic approaches, and therapeutic strategies, with a particular focus on fecal microbiota transplantation (FMT) as a single therapy acting on multiple disease axes. By restoring microbial equilibrium, FMT can modulate host immunity and reinforce epithelial integrity, collectively promoting mucosal healing. We summarize mechanistic evidence, findings from preclinical and clinical studies, and key variables influencing FMT efficacy, including donor selection, preparation, and delivery routes. While evidence supports the therapeutic promise of FMT, challenges remain regarding standardization, long-term engraftment, and sustained safety. Nonetheless, FMT represents a transformative therapeutic platform that redefines UC treatment by bridging microbial restoration, immune modulation, and barrier repair. Future research should aim to refine FMT protocols and develop next-generation microbiota-based therapeutics, such as defined microbial consortia and live biotherapeutic products, to enable safer, more consistent, and personalized modulation of the gut ecosystem in UC.

Source study →